Plain-English translation of NCT07075328 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing OJP-001, a new light-activated treatment, combined with an oral medication called 5-ALA, for adults with adult T-cell leukemia/lymphoma (ATLL) that has come back or is not responding to previous treatments. The study has two parts: first, doctors will test different doses to find the safest and most effective level, and then they will test the chosen dose and schedule in more patients. This medication works by using light to target and destroy cancer cells in the blood.
ATLL is a rare and aggressive blood cancer that can be very difficult to treat, especially when it comes back or stops responding to standard therapies. This trial exists to see whether this new light-activated treatment can help patients whose cancer is no longer responding to available options.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive an oral medication (5-ALA) followed by the light-activated treatment (OJP-001) during clinic visits. In the first part of the study, you'll receive one treatment to help doctors find the right dose. In the second part, if the treatment is working well, you'll come back once a week for 6 months to receive the medication and treatment together. Your doctors will monitor you with regular blood tests and check-ups to see how you're doing and watch for any side effects.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
Japan